Australija - anglų - Department of Health (Therapeutic Goods Administration)

integra neurosciences pty ltd - 46170 - skin regeneration template, human-/animal-derived - a bilayer membrane system for skin replacement. the dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate) that is manufactured with a controlled porosity and defined degradation rate. the epidermal substitute layer is made of a thin polysiloxane (silicone) layer to control moisture loss from the wound. it is indicated for the post excisional treatment of full-thickness and partial-thickness injuries where sufficient auto graft is not available at the time of excision or not desirable due to the physiological condition of the patient. integra dermal regeneration template is also indicated for use in reconstruction of post excisional, full-thickness defects of the integument where there is, in the opinion of the treating surgeon, a potential benefit to the patient by improving the reconstructive outcome or decreasing their mortality/morbidity.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

integra neurosciences pty ltd - 46170 - skin regeneration template, human-/animal-derived - a porous matrix of fibers of cross-linked bovine tendon collagen and a glycosaminoglycan (chondroitin-6-sulfate) that is manufactured with a controlled porosity and defined degradation rate. indicated to add extra thickness where required (to the integra bi-layer dermal replacement) for the postexcisional treatment of full thickness and partial-thickness injuries where sufficient autograft is not available at the time of excision or not desirable due to the physiological condition of the patient. it is also indicated for use in reconstruction of postexcisional, full-thickness defects of the integument where there is, in the opinion of the treating surgeon, a potential benefit to the patient by improving the reconstructive outcome or decreasing their mortality/morbidity.

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mavlab pty. ltd. - shark cartilage; abalone powder; stabilised green-lipped mussel powder - oral bolus, chewable - shark cartilage extract-animal active 200.0 g/kg; abalone powder food-general active 200.0 g/kg; stabilised green-lipped mussel powder vitamin active 600.0 g/kg - musculoskeletal system - dog | bitch | castrate | puppy - arthritis

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - idursulfase 2 mg/ml;   - concentrate for infusion - 2 mg/ml - active: idursulfase 2 mg/ml   excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride water for injection - elaprase is indicated for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii).

Izraelis - anglų - Ministry of Health

medison pharma ltd - galsulfase - concentrate for solution for infusion - galsulfase 1 mg/ml - galsulfase - galsulfase - naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mpsvi (n-acetylglactosamine 4 sulfatase deficiency maroteaux-lamy syndrome).

Singapūras - anglų - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human antithrombin - injection, powder, lyophilized, for solution - 1000 i.u. per 20ml - human antithrombin 1000 i.u. per 20ml

Singapūras - anglų - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human antithrombin - injection, powder, lyophilized, for solution - 500 i.u. per 10ml - human antithrombin 500 i.u. per 10ml

Singapūras - anglų - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - laronidase - injection, solution - 2.9mg - laronidase 2.9mg

Europos Sąjunga - anglų - EMA (European Medicines Agency)

biomarin international limited - recombinant human n-acetylgalactosamine-6-sulfatase - mucopolysaccharidosis iv - other alimentary tract and metabolism products, - vimizim is indicated for the treatment of mucopolysaccharidosis, type iva (morquio a syndrome, mps iva) in patients of all ages.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - galsulfase 1 mg/ml - concentrate for infusion - 1 mg/ml - active: galsulfase 1 mg/ml excipient: polysorbate 80 sodium chloride sodium phosphate water for injection - naglazyme is indicated as long term enzyme replacement therapy in patients with mucopolysaccharidosis vi (mps vi, n-acetylgalactosamine 4-sulfatase deficiency, maroteaux-lamy syndrome).